Cargando…

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study

The clinical characteristics of the rebound phenomenon after antiviral therapy in patients with Coronavirus disease-2019 (COVID-19) are largely unknown. There are few data comparing the rebound phenomenon after molnupiravir therapy to that after nirmatrelvir-ritonavir therapy. We investigated the in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jaijun, Bae, Seongman, Jung, Jiwon, Kim, Min Jae, Chong, Yong Pil, Lee, Sang-Oh, Choi, Sang-Ho, Kim, Yang Soo, Chang, Euijin, Kim, Sung-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	4900
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545339/ https://www.ncbi.nlm.nih.gov/pubmed/37773854 http://dx.doi.org/10.1097/MD.0000000000035094

Ejemplares similares

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Optimal duration of antiviral treatment in patients with gastrointestinal cytomegalovirus disease at a low and high risk of relapse
por: Jung, Kyung Hwa, et al.
Publicado: (2022)

Clinical features of patients with Legionnaires disease showing initial clinical improvement but radiological deterioration: A retrospective single-center analysis
por: Kim, Jinyeong, et al.
Publicado: (2021)

Comparison of chest radiographic findings between severe fever with thrombocytopenia syndrome and scrub typhus: Single center observational cross-sectional study in South Korea
por: Yun, Ji Hyun, et al.
Publicado: (2019)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Clinical Features and Outcomes of Spontaneous Bacterial Peritonitis Caused by Streptococcus pneumoniae: A Matched Case-Control Study
por: Kim, Taeeun, et al.
Publicado: (2016)

Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia
por: Kim, Taeeun, et al.
Publicado: (2017)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

515. The Impact of Prolonged Steroid Use on Critically Ill COVID-19 Patients: A Retrospective Cohort Study
por: Han, Jaijun, et al.
Publicado: (2023)

Diagnostic Usefulness of IFN-Gamma Releasing Assays Compared With Conventional Tests in Patients With Disseminated Tuberculosis
por: Yu, Shi Nae, et al.
Publicado: (2015)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

Molecular Characteristics and Prevalence of Rifampin Resistance in Staphylococcus aureus Isolates from Patients with Bacteremia in South Korea
por: Kim, Yong Kyun, et al.
Publicado: (2023)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
por: Park, Jin Ju, et al.
Publicado: (2023)

CT findings in viral lower respiratory tract infections caused by parainfluenza virus, influenza virus and respiratory syncytial virus
por: Kim, Min-Chul, et al.
Publicado: (2016)

Bacterial Co-Infection and Empirical Antibacterial Therapy in Patients With COVID-19
por: Lee, Jiyoung, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea
por: Yang, Eunmi, et al.
Publicado: (2021)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Birabaharan, Morgan, et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Zheng, Qian, et al.
Publicado: (2023)

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Clinical and radiologic characteristics of radiologically missed miliary tuberculosis
por: Choe, Jooae, et al.
Publicado: (2021)

Protracted course of SARS-CoV-2 pneumonia in moderately to severely immunocompromised patients
por: Lee, Jeongjae, et al.
Publicado: (2023)

Correction to: Protracted course of SARS‑CoV‑2 pneumonia in moderately to severely immunocompromised patients
por: Lee, Jeongjae, et al.
Publicado: (2023)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
por: Karniadakis, Ioannis, et al.
Publicado: (2023)

Is Follow-Up Endoscopy Necessary in Upper Gastrointestinal Cytomegalovirus Disease?
por: Seo, Myeongsook, et al.
Publicado: (2016)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ltd6u0u3g1md0dm2cog501js73